NKCx Histopathological outcome* within 12 months after cervix cytology in 2021 |
091 Huvudsta |
Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
Benign sample | 70 | 4.2% | 21 | 1.3% | 6 | 0.4% | . | . | . | . | . | . | 1566 | 94.2% | 1663 | 100.0% |
ASCUS | 37 | 28.7% | 27 | 20.9% | 11 | 8.5% | . | . | . | . | . | . | 54 | 41.9% | 129 | 100.0% |
LSIL | 25 | 23.6% | 38 | 35.8% | 13 | 12.3% | . | . | . | . | . | . | 30 | 28.3% | 106 | 100.0% |
Unclear atypia | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | . | . | 1 | 100.0% |
ASC-H | 4 | 19.0% | 6 | 28.6% | 10 | 47.6% | . | . | . | . | . | . | 1 | 4.8% | 21 | 100.0% |
HSIL | 5 | 14.7% | . | . | 24 | 70.6% | 1 | 2.9% | . | . | . | . | 4 | 11.8% | 34 | 100.0% |
Suspected Adenocarcinom | . | . | . | . | . | . | . | . | 1 | 50.0% | . | . | 1 | 50.0% | 2 | 100.0% |
Totalt | 141 | 7.2% | 92 | 4.7% | 65 | 3.3% | 1 | 0.1% | 1 | 0.1% | . | . | 1656 | 84.7% | 1956 | 100.0% |
NOTE: Histopathological outcome from T83x taken into account. |
This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
* Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
Snomed codes in the category Cancer: |
---|
M81403 |